<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T03:33:31Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/31470" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/31470</identifier><datestamp>2026-09-24T06:05:56Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Moayyedi, Paul</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Schünemann, Holger</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Santesso, Nancy</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Leontiadis, Grigorios</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Research Methodology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-04-07T15:41:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2025-04-07T15:41:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/31470</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/18378</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">BACKGROUND. Fecal calprotectin (FC) testing has been proposed as a replacement test for ileocolonoscopy in symptomatic patients with inflammatory bowel disease (IBD) to assess for endoscopic activity. &#xd;
OBJECTIVES. Primary: to characterize the diagnostic accuracy of FC testing for assessing endoscopic activity in symptomatic IBD patients.&#xd;
Secondary: to explore how diagnostic accuracy varies according to clinical, technical, and methodological characteristics. &#xd;
METHODS. We searched MEDLINE and Embase to February 8, 2024. We included single-gate diagnostic studies on symptomatic patients with IBD, adult or pediatric. Index test: laboratory-conducted quantitative immunochemical assays for FC, with positivity thresholds 50-300 μg/g. Stool samples were produced within seven days before the ileocolonoscopy but not after initiating bowel preparation. Target condition: Endoscopically active disease in the colon or terminal ileum. Reference standard: white-light-imaging ileocolonoscopy&#xd;
Two authors independently assessed study eligibility, extracted study data, and assessed methodological quality (with QUADAS-2) and certainty of evidence (GRADE approach). We intended to conduct the meta-analysis with the bivariate random effects model. We intended to investigate heterogeneity with predetermined subgroup analyses, sensitivity analyses and meta-regression analyses. &#xd;
The protocol was registered in PROSPERO (ID: CRD42023420120).&#xd;
RESULTS. We screened 7,398 abstracts and assessed 598 full-text publications. No study met the criteria for inclusion. By a post hoc protocol deviation, we contacted the authors of two marginally ineligible studies, acquired unpublished data and included the studies in an expansive sensitivity analysis (&lt;75% symptomatic participants). The certainty of evidence was very low due to serious (or very serious) risk of bias, serious imprecision, and serious indirectness. There were concerns about selective reporting bias. &#xd;
Methodological innovations: (a) enhanced QUADAS-2 instrument capturing the direction of the effect of the risk of bias; (b) the concept of expansive sensitivity analyses. &#xd;
CONCLUSIONS. Despite the common use of FC testing in symptomatic patients with IBD, no study has evaluated its diagnostic accuracy.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">fecal calprotectin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">diagnostic accuracy</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">inflammatory bowel disease</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">systematic review and meta-analysis</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Diagnostic accuracy of fecal calprotectin testing for assessing endoscopic activity of disease in symptomatic patients with inflammatory bowel disease: a systematic review and meta-analysis</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>